SURMOUNTing body weight barriers in type 2 diabetes

Aaron Novikoff; Timo D Müller

doi:10.1016/j.medj.2023.11.007

SURMOUNTing body weight barriers in type 2 diabetes

Med. 2023 Dec 8;4(12):849-851. doi: 10.1016/j.medj.2023.11.007.

Authors

Aaron Novikoff¹, Timo D Müller²

Affiliations

¹ Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
² Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany. Electronic address: timodirk.mueller@helmholtz-munich.de.

PMID: 38070476
DOI: 10.1016/j.medj.2023.11.007

Abstract

The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues set out to examine the weight loss efficacy of the GIPR:GLP-1R co-agonist tirzepatide in patients with obesity and type 2 diabetes, reporting that tirzepatide has unprecedented efficacy in a magnitude historically considered almost unattainable.¹.

MeSH terms

Anti-Obesity Agents* / therapeutic use
Diabetes Mellitus, Type 2* / drug therapy
Humans
Obesity / drug therapy
Weight Loss

Substances

Anti-Obesity Agents